The Academic Concierge Division capitalizes on LLS's academic grant-supported portfolio of development-stage projects. This division supports the further development of selected academic projects (with or without prior LLS grant support) to gain clinical proof of concept. Successful projects will potentially be advanced for further clinical development by creating additional partnerships with pharmaceutical or biotechnology companies.
TAP funding is different from the traditional grant at LLS. The TAP review process is separate from the grant process and each approved project is closely monitored by TAP staff.
For information on how to apply to TAP, please click here.
Clinical Studies Ongoing
Johns Hopkins University and The Leukemia & Lymphoma Society
Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
This research is being done to find out if altering the immune system by giving activated marrow-infiltrating lymphocytes (aMILs) and Tadalafil can improve outcomes for high risk multiple myeloma patients who receive a standard autologous stem cell transplant.
ClinicalTrials.gov identifier: NCT01858558
For more information contact:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231
Visit the Johns Hopkins University website for additional information.
Oregon Health & Science University and The Leukemia & Lymphoma Society
CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia (Active, Not Yet Recruiting)
This phase II trial studies how well FMS inhibitor JNJ-40346527 works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. FMS inhibitor JNJ-40346527 may stop the growth of cancer cells by blocking some of the microenvironmental signals needed for cell growth.
Participants receive FMS inhibitor JNJ-40346527 orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up within 2 weeks, at 4-6 weeks until death or minimum of 12 months.
ClinicalTrials.gov identifier: NCT03557970
For more information contact the recruiting sites:
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239
Contact: Elie Traer, MD 503-494-7999
Principal Investigator: Elie Traer, MD
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States, 75390
Contact: Robert Collins
Visit the Oregon Health & Science University Knight Cancer Institute website for additional information.
MD Anderson and The Leukemia & Lymphoma Society
Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This clinical research study has 2 parts: dose escalation and dose expansion. The goal of dose escalation in this clinical research study is to find the best dose of IACS-010759 that can be given to patients with relapsed or refractory AML. The goal of dose expansion in this clinical research study is to learn if the dose of IACS-010759 found in the dose escalation part of the study is the best dose to use in future studies using IACS-010759 in patients with AML. The safety and tolerability of this drug will also be studied. This is the first study using IACS-010759 in humans.
ClinicalTrials.gov identifier: NCT02882321
For more information contact:
Marina Konopleva, MD, PHD
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Visit the MD Anderson website for additional information.
Case Western Reserve and The Leukemia & Lymphoma Society
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
This is a phase I study with "3+3" design with three planned dose levels of NK cells and a fixed dose of ALT-803. Three patients will be enrolled sequentially to each dose level, starting with dose level 1. Patients will be segregated to either receive ALT803 as cytokine support after NK cell infusion (starting with same dose level as Level 1) or no cytokine administration. Patients in the arm receiving ALT803 will be either hematologic malignancy patients (Cohort A) or Colon/Soft tissue sarcoma patients (Cohort B). Absence of dose limiting toxicity (DLT) in the DLT assessment period of 28 days must be documented for all patients enrolled a cell dose without ALT803 before the next cohort of patients to receive cytokines at that dose level can be enrolled. Patients can also be enrolled in parallel to the next cell dose level without cytokines.
ClinicalTrials.gov identifier: NCT02890758
For more information contact:
David Wald, MD, PhD
University Hospitals Cleveland Medical Center
Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
Visit the Case Western Reserve website for additional information.
Other Active Programs
If you'd like your organization to be considered for TAP funding, you must meet the following criteria:
Your organization must have active proprietary projects in the blood cancer field.
Your project must be at a late preclinical or an early clinical development stage.
The compounds, biologics or diagnostics in development must have a high, near-term probability of providing benefits to patients.
The funding TAP provides is not a grant.
LLS's TAP team reviews all organizations that make an inquiry but will only invite those deemed to meet diligence criteria to complete a proposal template and be considered for TAP funding.
To submit an inquiry for initial non-confidential review, contact Dr. Jun Xu, Executive Director, Therapy Acceleration Program®, The Leukemia & Lymphoma Society, 3 International Drive, Suite 200, Rye Brook, NY 10573; firstname.lastname@example.org.